{"nctId":"NCT02095158","briefTitle":"A Long-Term Safety and Efficacy Study AGN-19920 in Patients With Persistent Erythema Associated With Rosacea","startDateStruct":{"date":"2014-04"},"conditions":["Erythema","Rosacea"],"count":440,"armGroups":[{"label":"Oxymetazoline HCL Cream 1.0%","type":"EXPERIMENTAL","interventionNames":["Drug: Oxymetazoline HCL Cream 1.0%"]}],"interventions":[{"name":"Oxymetazoline HCL Cream 1.0%","otherNames":["AGN-199201"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n-Moderate to severe persistent facial erythema associated with rosacea.\n\nExclusion Criteria:\n\n* Current treatment with monoamine oxidase (MAO) inhibitors\n* Raynaud's syndrome, narrow angle glaucoma, orthostatic hypotension, scleroderma or Sjogren's syndrome.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With Treatment-Related Adverse Events","description":"An adverse event was considered any unfavorable and unintended sign, symptom, or disease associated with the use of the study drug, whether or not considered related to the study drug. A Treatment-Related Adverse Event is an Adverse Event determined by the investigator to be causally related to the study medication.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With at Least a 2-Grade Decrease From Baseline on Both Clinician Erythema Assessment (CEA) and Subject Satisfaction Assessment (SSA) Using 5-Point Scales","description":"The investigator assessed the participant's overall severity of erythema in the treatment area by using the 5-point CEA scale with photonumeric guide where: 0=clear skin with no signs of erythema (best) to 4=severe erythema; fiery redness (worst). A decrease in the score indicates improvement. The participant assessed their overall severity of rosacea facial redness in the treatment area by using the 5-point SSA scale with photoguide where: 0=no signs of unwanted redness (best) to 4=severe redness (worst). A decrease in the score indicates improvement. The percentage of participants with at least a 2-grade decrease (improvement) on both CEA and SSA from Baseline was evaluated over the 6-hour evaluation period (hours 3 and 6) post-dose.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"23.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"34.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"38.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"36.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"43.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12.1","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":15,"n":440},"commonTop":[]}}}